Australia markets closed

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.42-0.02 (-0.27%)
At close: 04:00PM EDT
7.44 +0.02 (+0.27%)
After hours: 05:12PM EDT

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees265

Key executives

NameTitlePayExercisedYear born
Dr. Gilmore O'Neill M.D.President, CEO & Director815.37kN/A1965
Dr. Baisong Mei M.D., Ph.D.Senior VP & Chief Medical Officer386.99kN/AN/A
Dr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/A1954
Dr. J. Keith Joung M.D., Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/AN/A
Mr. Erick J. Lucera C.F.A., CPACFO & Executive VPN/AN/A1968
Dr. Linda C. Burkly Ph.D.Executive VP & Chief Scientific OfficerN/AN/AN/A
Cristi BarnettCorporate Communications & Investor RelationsN/AN/AN/A
Ms. Charlene Stern J.D., Ph.D.Executive VP & General CounselN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Corporate governance

Editas Medicine, Inc.’s ISS governance QualityScore as of 1 March 2024 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.